Product Description
ACI-24 is a liposome vaccine designed to elicit an antibody response against aggregated A_ peptides without concomitant pro-inflammatory T cell activation. This vaccine grew out of work with tetrapalmitoylated preparations of N-terminal A_ fragments, which rapidly stimulated anti-A_ antibodies that dissolve amyloid fibers in vitro and in vivo. ACI-24 is based on the truncated A_-15 sequence, which is devoid of T-cell epitopes located closer to the peptideÕs C-terminus. (Sourced from: https://www.alzforum.org/therapeutics/aci-24)
Mechanisms of Action: Vaccine,AB
Novel Mechanism: Yes
Modality: Vaccine
Route of Administration: Injection
FDA Designation: Fast Track - Alzheimer Disease *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additional Commercial Interests: AC Immune
Clinical Description
Countries in Clinic: Spain, United Kingdom
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
- Clinical Outcomes Expected - AC Immune announced they will present P2 Parkinson's Disease results in 2H25 for ACI-24
- Clinical Outcomes Reported - AC Immune presented P1 Alzheimer Disease results on 2025-04-02 for ACI-24
- Clinical Outcomes Expected - AC Immune announced they will present P1 Alzheimer Disease|Down Syndrome results in YE25 for ACI-24
Highest Development Phases
Phase 2: Alzheimer Disease|Amyloidosis|Down Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ACI-24-AD-DS-2102 | P2 |
Recruiting |
Alzheimer Disease |
2026-07-31 |
12% |
2025-05-02 |
Treatments |
| ABATE Study | P2 |
Recruiting |
Down Syndrome|Amyloidosis|Alzheimer Disease |
2026-06-01 |
12% |
2022-07-19 |
Primary Endpoints|Treatments |